Moderna, Inc. MRNA

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
47/100
Developing

Ranked against 712 peers in Biotechnology

About Moderna, Inc.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial … Full MRNA analysis →

Key strengths

  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.82), demonstrating pricing resilience across cycles.
  • Consistent Cash Generation Cash generation is strong and consistent (score 0.70).

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.31), raising refinancing risk.
  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.08), suggesting weak customer stickiness.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
47
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where MRNA ranks in Biotechnology

Moderna, Inc. ranks #272 of 713 scored companies in Biotechnology by moat score — the top 38%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
268 Intellia Therapeutics, Inc. NTLA 48/100 Developing
269 Olema Pharmaceuticals, Inc. OLMA 48/100 Developing
270 Kymera Therapeutics, Inc. KYMR 47/100 Developing
271 LENZ Therapeutics, Inc. LENZ 47/100 Developing
272 Moderna, Inc. MRNA 47/100 Developing
273 Relmada Therapeutics, Inc. RLMD 47/100 Developing
274 Bright Minds Biosciences Inc. DRUG 47/100 Developing
275 Janux Therapeutics, Inc. JANX 47/100 Developing
276 Bolt Biotherapeutics, Inc. BOLT 47/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How MRNA scores on the Corporate Default defenses

Pricing Power

Score 47 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 73 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 45 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 38 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 41 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 43 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding MRNA's moat

What is Moderna, Inc.'s moat score?

Moderna, Inc. (MRNA) scores 47 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #272 of 713 scored companies in Biotechnology, the top 38%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Cost Advantage (73/100) and its weakest is Capital Efficiency (38/100).

How does Moderna, Inc. compare with other Biotechnology companies?

Moderna, Inc. ranks #272 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are LENZ Therapeutics, Inc. (LENZ) at 47 just above it and Relmada Therapeutics, Inc. (RLMD) at 47 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Moderna, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Moderna, Inc.?

The Corporate Default template measures 6 defenses, and MRNA scores: Pricing Power (47), Cost Advantage (73), Customer Stickiness (45), Capital Efficiency (38), Resilience (41), Scale & Market Position (43). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000